Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration

Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

(2021) Ana Bety Enríquez et al.   JAMA Ophthalmology

Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment

(2021) David Braun et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses

(2021) Mehmet Ali Sekeroglu et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab

(2020) Caroline R. Baumal et al.   OPHTHALMOLOGY

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

(2020) Jordi Monés et al.   OPHTHALMOLOGY

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

(2019) Pravin U. Dugel et al.   OPHTHALMOLOGY

Age-Related Macular Degeneration Preferred Practice Pattern®

(2019) Christina J. Flaxel et al.   OPHTHALMOLOGY

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti–VEGF Drug Type for 1 Year in the IRIS Registry

(2018) Prethy Rao et al.   OPHTHALMOLOGY

The American Academy of Ophthalmology's IRIS ® Registry (Intelligent Research in Sight Clinical Data): A Look Back and a Look to the Future

(2017) David W. Parke et al.   OPHTHALMOLOGY

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

(2015) Alberto Ferreira et al.   PLoS One

Risk of Relapse in Primary Acute Anterior Uveitis

(2011) Lili Grunwald et al.   OPHTHALMOLOGY